| Literature DB >> 26046518 |
Mark Lazari1, Serge K Lyashchenko2, Eva M Burnazi2, Jason S Lewis3, R Michael van Dam1, Jennifer M Murphy4.
Abstract
Noninvasive in vivo imaging of androgen receptor (AR) levels with positron emission tomography (PET) is becoming the primary tool in prostate cancer detection and staging. Of the potential (18)F-labeled PET tracers, (18)F-FDHT has clinically shown to be of highest diagnostic value. We demonstrate the first automated synthesis of (18)F-FDHT by adapting the conventional manual synthesis onto the fully-automated ELIXYS radiosynthesizer. Clinically-relevant amounts of (18)F-FDHT were synthesized on ELIXYS in 90 min with decay-corrected radiochemical yield of 29±5% (n=7). The specific activity was 4.6 Ci/µmol (170 GBq/µmol) at end of formulation with a starting activity of 1.0 Ci (37 GBq). The formulated (18)F-FDHT yielded sufficient activity for multiple patient doses and passed all quality control tests required for routine clinical use. Published by Elsevier Ltd.Entities:
Keywords: FDHT; Fluorine-18; Fully-automated; LiAlH(4) reduction; PET; Prostate cancer
Mesh:
Substances:
Year: 2015 PMID: 26046518 PMCID: PMC4530021 DOI: 10.1016/j.apradiso.2015.05.010
Source DB: PubMed Journal: Appl Radiat Isot ISSN: 0969-8043 Impact factor: 1.513